Happy New year and Best Wishes from Imavita for 2024!
IMAVITA and all its team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2024!
Scientific paper release / Acne model
We are pleased to announce that Imavita team recently co-authored a publication with
Ipsen about AbobotulinumtoxinA improvement on skin properties and sebum quality in Rhino mouse acne model. The paper was released in Toxicon Volume 233, on September 2023 and is fully available on-line:
https://doi.org/10.1016/j.toxicon.2023.107230
Thank you to all collaborators and team for this collaborative work!
Abstract:
Besides neuronal cells, botulinum neurotoxins (BoNTs) can also affect other cell types such as fibroblasts or keratinocytes. These cells play a key role in skin conditions. Maintaining a high-quality sebum secretion is essential to avoid premature aging. This study explored the effect of abobotulinumtoxinA (aboBoNT-A) in the rhino mouse. Briefly, anaesthetized animals were injected via the intra-dermal route (ID; four sites of injection) by either vehicle or 0.1, 0.3 and 1 Unit aboBoNT-A per mouse. A reference group was administered with adapalene gel 0.1% (daily local application) for 15 days. Adapalene is a third-generation retinoid and is used as first-line treatment of moderate acne. The body weight and the thickness of the dorsal skin were measured on days 1, 5, 10 and 15; erythema and scaling were recorded at the same time. On day 15, animals were ethically euthanized and skin samples were collected for histology, ELISA and lipidomic assays. AboBoNT-A administered ID at the doses 0.1 U and 0.3 U per mouse was well tolerated. 1 U aboBoNT-A (per mouse) induced a transient loss of muscle tone associated with a slight body weight loss after which mice recovered a good health status. AboBoNT-A did not show any significant effect on utricles surface area but induced a significant anti-inflammatory effect on dermis at the two highest doses. Moreover, aboBoNT-A showed neither side effects commonly observed with local retinoids, nor hyperplasia or dermis inflammation. No change in skin Interleukin-1alpha (IL-1α) cytokine levels was evidenced with aboBoNT-A, whereas a dose-dependent increase of substance P (SP) concentration in the skin was recorded, suggesting that aboBoNT-A induces neuropeptide accumulation in tissue by inhibiting exocytosis mechanisms. Lipidomic analysis showed that aboBoNT-A significantly increased the sebum concentration of several lipid species, presenting skin protecting properties. Overall, these data suggest that ID aboBoNT-A has skin rejuvenation, anti-inflammatory and moisture-boosting properties.
New equipment Bioluminescence BLI / Fluorescence FLI
Imavita is proud to announce the recent acquisition of a new Bioluminescence imaging (BLI 2D/3D) / Fluorescence imaging (FLI 2D) imaging apparatus to help in development of preclinical models.
Since December 2022, Imavita is working on this innovative imaging system (Newton 7.0 / Vilber) which will permit to generate non-invasive, bioluminescence imaging (BLI) and fluorescence imaging (FLI) quantitative data for pre-clinical models in place at Imavita in Applications of interest, and principally in the area of drug disposition (PK and PK/PD), oncology, osteo-articular disease and dermatology.
Bioluminescence imaging / BLI is available in 2D, but also in 3D (BLI tomography). Fluorescence imaging (FLI) is available in 2D.
This new apparatus will permit in vivo and ex vivo imaging for:
- Monitoring the development of tumors and infections
- Tracking cell migration
- Targeting Biodistribution of drugs, molecules and nanoparticles
- Visualization of vasculature and microcirculation
The benefits of this in vivo imaging modality are:
- Easily and efficiently obtain calibrated quantitative data in preclinical models
- Deepen understanding of disease mechanisms, disease progression and therapeutic responses
- Manage costs and capture time course data by avoiding sacrifice of animal models
For more informations, do not hesitate to contact us.
Happy New year and Best Wishes from Imavita for 2023!
IMAVITA and all its team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2023!
This year our company IMAVITA is 10 years old!
Thanks to our customers, collaborators, partners, friends & family for continuous support over these 10 years!
Click on the image below to see animation:
Poster release / Acne model
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies released a poster related to efficacy of BoNT in Rhino mouse model of acne:
Poster summary available on Sciencedirect website page and pdf of abstract is available.
Poster was presented at Toxins 2022 congress, New-Orleans, USA.
The team is growing / New team members
Imavita is proud to announce new team members with the recent recruitment of Pierre-Yves Fortin and Pauline Auriol.
Pierre-Yves Fortin, PhD, Preclinical imaging, Project Leader, Pierre-Yves is a PhD graduated on 2011 and Post-Doc in 2020 with an important background and experience with preclinical models, preclinical imaging (fluorescence, bioluminescence, ultrasonography, elastography, etc…) in oncology.
Pauline Auriol, Apprentice Bachelor Degree (BSc), Research Scientist Assistant. Pauline is actually graduating Vocational Bachelor’s Degree in Analytical and Experimental Biology from University of Montpellier, France.
Pauline works now at Imavita with in vivo models for drug efficacy evaluation principally.
Happy New year and Best Wishes from Imavita for 2021!
IMAVITA and all is team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2021!
In 2021, add scientific value to your preclinical research projects with IMAVITA!
Click on the image to see animation:
Some words on Imavita’s season’s greetings eCard:
- PET/CT images of mice are presented (89Zr PET/CT / CT alone / SPECT/CT)
- A black mouse is presented with its mirror Magnetic Resonance image (MRI)
- Wishes for the New Year are translated in different languages
The team is growing
Imavita is proud to announce a new team member with the recent recruitment of Claire Coustal.
Claire Coustal, Apprentice MSc, Research Scientist Assistant. Claire is actually graduating Master 2 (M2) Innovating Drug therapies and Biotherapeutics (“Biothérapies et Médicaments de Thérapie Innovante”) from University of Nantes, France.
Claire works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation principally in the field of Osteo-Articular disease and Neurology/Neuro-Inflammation.
Imavita, partner in PICSTEM project / Collaborative Project in Production of Adipous Tissue-derived Stem Cells
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies associated with imaging and image analysis, announces its participation in the collaborative project PICSTEM.
This 2-years project will focus on the fields of osteo-articular diseases (Psoriatic Arthritis, Osteo-Arthritis and Ankylosing Spondyloarthritis) and neurology (neuro-inflammation in Recurrent-Remittent Multiple Sclerosis and Sciatic nerve inflammation).
IMAVITA will actively participate in this project by providing technical and scientific expertise and relevant preclinical models of human pathologies.
This project will allow IMAVITA to develop new animal models and develop new translational services in preclinical and clinical imaging.
Partners participating in PISCTEM project:
Cell-Easy https://cell-easy.com
Imavita https://imavita.com
Stromalab https://www.stromalab.fr/en/
Ambiotis
Future Events / Congresses / Formations
Imavita will attend the following future events / congresses / formations:
- World Molecular Imaging Congress 2020 / WMIC Virtual 2020 – October 6th to 9th 2020
- Toulouse OncoWeek 2020 / TOW2020 – Toulouse / France – February 1st to 5th 2020
We will be pleased to discuss with you about science, collaborations and innovating services at these events.
Do not hesitate to contact us before if you are interested in setting up a meeting with attending people of our company.